Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

NCT06606093 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

348

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetic Nephropathy

Interventions

DRUG: DWP16001 Placebo
DRUG: DWP16001 0.3mg

Sponsor

Daewoong Pharmaceutical Co. LTD.